Gram-Negative Bacteria Dominated One Mumbai Hospital’s Isolates
The strongest descriptive finding is the predominance of Gram-negative bacteria in one hospital’s isolate records, while the thyroid associations and experimental peptide-delivery results remain distinct, design-limited findings.
Evidence
Gram-negative bacteria accounted for 1,627 of 2,075 clinically significant isolates—78.4%—at Bhatia Hospital in Mumbai. Gram-negative denotes a broad bacterial group distinguished by a laboratory staining test. In the same collection, 597 isolates, or 28.8%, were multidrug-resistant, meaning resistant to multiple antimicrobial drugs. These percentages describe laboratory isolates, not the proportion of patients with resistant infections.
The hospital surveillance study, published September 19, 2026, retrospectively reviewed non-duplicate bacterial and fungal isolates from inpatient and outpatient specimens collected during January–December 2025. Identification used standard microbiological methods and the VITEK 2 Compact automated system; drug-susceptibility testing used that system and was interpreted under 2025 laboratory guidelines.
The Iranian lichen planus study, also published September 19, compared 70 patients with lichen planus, an inflammatory skin condition, with 70 age- and sex-matched controls. Conducted at Razi Hospital in Tehran during 2023–2024, it used dermatologist examination and biopsy to confirm diagnoses.
Antibodies against thyroid peroxidase, a thyroid enzyme, were higher in patients by a mean of 54.3. The 95% confidence interval—a measure of statistical uncertainty around the estimate—was 36.1–72.5; units for this overall comparison were not specified. Thyroid-stimulating hormone was higher by 1.59 micro-international units per milliliter, with a 95% confidence interval of 0.20–2.98. Free thyroxine, the unbound form of a thyroid hormone, was lower, but that difference was not statistically significant.
The glioblastoma peptide-delivery study, published September 1, tested peptides—short amino-acid chains—in brain-cancer cell lines and a laboratory blood–brain barrier model using HBEC-5i cells. The blood–brain barrier limits movement of substances from blood into the brain. Replacing tyrosine, one amino-acid component of the parent peptide, with either cyclohexylalanine or 1-naphthylalanine increased cellular uptake two- to fourfold. A construct linking the shuttle peptide to an inhibitor crossed the laboratory barrier model and functionally silenced miR-21-5p, a small RNA involved in regulating gene activity, in glioblastoma cells.
Analysis
Interpretation: The hospital findings directly describe one institution’s organism distribution and resistance burden. The skin study identifies an association between lichen planus and thyroid-related laboratory measurements. The peptide study demonstrates delivery and silencing functions within laboratory models, not a therapeutic outcome.
Their shared lesson concerns evidence boundaries, not a shared biological mechanism. Different populations, models and measurements prevent any of these studies from independently confirming the others.
Limitations
The hospital review was retrospective and single-center. It did not examine patient-level antibiotic exposure or treatment outcomes, and it did not characterize resistance genes. Its isolate proportions cannot establish patterns across Mumbai or other hospitals.
The skin study’s modest sample and incomplete control of factors beyond age and sex limit interpretation. Its case-control design cannot establish whether thyroid-marker changes preceded lichen planus or whether another factor contributed to both.
For the peptide experiments, sample size and quantitative magnitudes of barrier passage and silencing were not available in the reported findings. Laboratory barrier passage does not establish delivery across the human blood–brain barrier or clinical benefit.
What to watch
Larger, prospectively followed lichen planus groups with broader adjustment for confounding could test whether the thyroid-marker association persists. For the peptide construct, quantified barrier passage, silencing and downstream target-expression changes would help establish how consistently delivery produces the intended biological effect.
For the lead finding, comparable multi-hospital surveillance showing similar Gram-negative and multidrug-resistant isolate proportions after accounting for clinical-area mix would increase confidence that the Mumbai pattern extends beyond one institution.